ProfileGDS5678 / 1421480_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 13% 13% 12% 18% 12% 12% 13% 13% 13% 13% 13% 13% 13% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4147616
GSM967853U87-EV human glioblastoma xenograft - Control 22.3272713
GSM967854U87-EV human glioblastoma xenograft - Control 32.3270513
GSM967855U87-EV human glioblastoma xenograft - Control 42.2652112
GSM967856U87-EV human glioblastoma xenograft - Control 52.3946218
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3609112
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3309812
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3043313
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3099513
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3084313
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3165413
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3025213
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3176113
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3113813